These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 26648746)
1. Gastrointestinal events and association with initiation of treatment for osteoporosis. Modi A; Siris ES; Tang J; Sajjan S; Sen SS Clinicoecon Outcomes Res; 2015; 7():603-13. PubMed ID: 26648746 [TBL] [Abstract][Full Text] [Related]
2. Association between gastrointestinal events and osteoporosis treatment initiation in women diagnosed with osteoporosis in France: a retrospective analysis. Cortet B; Modi A; Tang J; Fan CP; Sajjan S; Weaver JP BMC Musculoskelet Disord; 2016 Apr; 17():195. PubMed ID: 27139225 [TBL] [Abstract][Full Text] [Related]
3. Association of gastrointestinal events with osteoporosis treatment initiation and treatment compliance in Germany: An observational study. Modi A; Fan CS; Tang J; Weaver JP; Sajjan S Bone Rep; 2016 Dec; 5():208-213. PubMed ID: 28580388 [TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis. Modi A; Siris ES; Steve Fan CP; Sajjan S Clin Ther; 2015 Jun; 37(6):1228-34. PubMed ID: 25866298 [TBL] [Abstract][Full Text] [Related]
5. Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage. Siris ES; Yu J; Bognar K; DeKoven M; Shrestha A; Romley JA; Modi A Clin Interv Aging; 2015; 10():1813-24. PubMed ID: 26604724 [TBL] [Abstract][Full Text] [Related]
6. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Siris ES; Modi A; Tang J; Gandhi S; Sen S Curr Med Res Opin; 2014 Jan; 30(1):123-30. PubMed ID: 24102262 [TBL] [Abstract][Full Text] [Related]
7. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. Modi A; Sajjan S; Michael Lewiecki E; Harris ST; Papadopoulos Weaver J Clin Ther; 2016 May; 38(5):1074-80. PubMed ID: 27112533 [TBL] [Abstract][Full Text] [Related]
8. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population. Modi A; Siris S; Yang X; Fan CP; Sajjan S J Manag Care Spec Pharm; 2015 Jun; 21(6):499-506. PubMed ID: 26011551 [TBL] [Abstract][Full Text] [Related]
9. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis. Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417 [TBL] [Abstract][Full Text] [Related]
10. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women. Yu J; Goldshtein I; Shalev V; Chodick G; Ish-Shalom S; Sharon O; Modi A Int J Clin Pract; 2015 Sep; 69(9):1007-14. PubMed ID: 26278464 [TBL] [Abstract][Full Text] [Related]
11. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598 [TBL] [Abstract][Full Text] [Related]
12. Association Between Gastrointestinal Events and Health Care Resource Utilization Among Patients with Osteoporosis: Analysis of a U.S. Managed Care Population. Modi A; Gold DT; Yang X; Fan CP; Sajjan SG J Manag Care Spec Pharm; 2015 Sep; 21(9):811-21. PubMed ID: 26308228 [TBL] [Abstract][Full Text] [Related]
13. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study. Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061 [TBL] [Abstract][Full Text] [Related]
14. Association between gastrointestinal events and compliance with osteoporosis therapy. Siris ES; Fan CS; Yang X; Sajjan S; Sen SS; Modi A Bone Rep; 2016 Jun; 4():5-10. PubMed ID: 28326336 [TBL] [Abstract][Full Text] [Related]
15. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Modi A; Siris ES; Tang J; Sen S Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017 [TBL] [Abstract][Full Text] [Related]
16. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910 [TBL] [Abstract][Full Text] [Related]
17. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644 [TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for prevention of postmenopausal osteoporosis. Ravn P Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721 [TBL] [Abstract][Full Text] [Related]
19. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248 [TBL] [Abstract][Full Text] [Related]
20. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race. Antonelli M; Einstadter D; Magrey M J Clin Densitom; 2014; 17(4):479-83. PubMed ID: 24657109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]